A new PET scan tracer, 68Ga-PFD3, to find and assess small cell lung cancer
Tests the 68Ga-PFD3 scan tracer for diagnosing small cell lung cancer in adults.
Key facts
- Who runs it
- Peking University First Hospital
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 30 people, planned
- Started
- 22 Oct 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Sequential [18F]-FDG PET/CT
- [68Ga]Ga-PFD3 PET/CT scan
- Record updated
- 18 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with small cell lung cancer confirmed by tissue examination. It tests a new PET scan tracer called 68Ga-PFD3.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Small cell lung cancer confirmed by tissue examination, with at least one lesion of 1 cm (0.4 in) or larger seen on standard imaging.
- Earlier treatment
- People who had earlier treatment targeting DLL3 cannot join.
Main reasons for not taking part
- Pregnancy
- Breastfeeding
- Acute psychiatric disorders
- Cannot have a PET scan, for example because of claustrophobia or weight limits
- Earlier therapy targeting DLL3
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults
- Histologically confirmed small cell lung cancer (SCLC)
- At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities
- Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment
Who cannot take part
- Prior therapy targeting DLL3
- Acute psychiatric disorders
- Pregnancy
- Breastfeeding
- Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications)
- Inability to complete the study procedures as anticipated
Where in China
- Peking university first hospital nuclear medicineBeijing, ChinaContact: Tingting Yuan, M. D.Taking people
About the trial
What the trial wants to find out
This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
The group in the trial
- Eligible participantsTreatment being tested
Sequential \[18F\]-FDG PET/CT and \[68Ga\]Ga-PFD3 PET/CT
Treatment: Sequential [18F]-FDG PET/CT and [68Ga]Ga-PFD3 PET/CT scan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET/CT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)
- Plain-language title
- A new PET scan tracer, 68Ga-PFD3, to find and assess small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 June 2026